Adrian Newman-Tancredi
is co-founder and
Chief Scientific Officer
of
Neurolixis Inc.

 

News

Adrian Newman-Tancredi, PhD, DSc, gave an invited lecture on Monday 19 January 2015 at the highly-recognized School of Physiology and Pharmacology of Bristol University (UK). The...Read More
Neurolixis, a bioscience company co-founded by Adrian Newman-Tancredi, has announced a drug discovery collaboration with Jagiellonian University in Krakow, Poland. The collaboration...Read More
Adrian Newman-Tancredi will be chairing a session at the World Orphan Drug Congress in Brussels, Belgium, on 12th to 14th October 2014. Dr. Newman-Tancredi has been invited to chair...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.

 
  •  

     

     

    NeuroAct Communication

    offers professional and independent advice

    at each stage of early CNS drug discovery. 

     

    Consulting Services

    Contact

  •  

    Newsletter

    Read the latest news from NeuroAct Communication

     


     

    November 2014

    April 2014

  •  

     

     

    NeuroAct Communication  

    was founded by Adrian Newman-Tancredi PhD DSc

    an experienced industrial neuropharmacologist.

     

    Executive Profile

    Endorsements

  •  

      

    Expertise in CNS Drug Discovery

    Preclinical pharmacology of antipsychotics,
    antidepressants, anti-Parkinsonian drugs and analgesics.   

     

    Read more

     

    ClozapineF-15599Milnacipran